On April 22nd, the first Boao Clinical Research Summit Forum was successfully held in Boao, Hainan.
The conference, with the theme of "Connecting Patients and Hope", set up a main forum for the opening ceremony, as well as three sub forums: "New Target Treatment for Lung Cancer", "New Drug Treatment for Alzheimer's Disease (AD)", and "New Drug Treatment for Inflammatory Bowel Disease (IBD) in the Digestive Field". More than 200 well-known domestic medical experts, scholars in related fields, and guests were invited to share the forefront of clinical research innovation and development through achievements sharing, practical reports Discussing hot topics in the form of gathering medical forces, focusing on patients, and relying on innovative policies in Lecheng Pilot Zone, we will jointly assist in the research and development and implementation of new drugs in China.
At the opening ceremony, Fu Zhu, a member of the Party Committee and Deputy Director of the Lecheng Management Bureau, as well as the Vice President of Hainan Zhenyan Institute, made a presentation titled "The Covenant of Lecheng". She introduced the location, policy, and institutional advantages of the Lecheng Pilot Zone, as well as the integration of industry and city, as well as the development of the medical and pharmaceutical industries, development goals, and key directions for attracting investment, to the guests from three aspects: the "unique Lecheng, the thriving Lecheng, and the Lecheng embracing tomorrow". With the continuous deepening of the reform and opening up of Hainan Free Trade Port and the release of policy dividends, the 'golden signboard' of Lecheng Pilot Zone is continuously unleashing its charm. It is favored by domestic medical institutions, pharmaceutical device research and development institutions, and globally renowned pharmaceutical device enterprises, and has established deep cooperative relationships with Lecheng Pilot Zone to accelerate the implementation of international innovative pharmaceutical device products in Lecheng.
She stated: Taking advantage of the convening of this summit forum, the Lecheng Management Bureau cordially invites the deans and experts present to participate in the construction of the Lecheng Pilot Zone. Through joint construction of hospitals, establishment of characteristic specialties, multi-point practice, and the use of the Lecheng Medical Industry Transformation Platform, we will assist in the construction of Lecheng's characteristic medical disciplines, provide patients with multi-level and diversified medical services, and promote medical technology innovation and product transfer Incubation
Gu Zhidong, Secretary of the Party Committee and Dean of Hainan Hospital (Hainan Boao Research Hospital) affiliated with Shanghai Jiao Tong University School of Medicine Ruijin Hospital, stated that relying on the "first try" policy, Lecheng Pilot Zone has gathered globally leading advanced resources and is a "city of hope" for patients to seek medical treatment and seek medicine. This summit forum adheres to the practice of conducting international multicenter clinical research in multiple regions of China, combined with the innovative pharmaceutical policy of Lecheng Pilot Zone and the implementation experience of this policy at Ruijin Hainan Hospital, to share clinical research experience in practicing patient-centered drug research and development. We hope to help patients find new and good drugs with the joint efforts of all parties.
Lin Feng, Chairman of Home Credit Pharmaceuticals/Xinhua Pharmaceuticals, introduced the development of Home Credit Pharmaceuticals and Xinhua Pharmaceuticals to the attending guests. Shanghai Jiexin Pharmaceutical Technology Co., Ltd. was established in 2008 and is a leading digital patient solution enterprise in the pharmaceutical industry in China. Home Credit Pharmaceuticals focuses on innovation and continues to build digital tools and platforms such as the "Light of New Drugs" and the "Medicine Finder". By utilizing digital technology, we efficiently connect pharmaceutical companies, hospitals, doctors, and patients, and collaborate with over 800 new drug clinical partners, covering over 250 cities and involving over 100 disease fields. We have collaborated with over 1800 hospitals, serving a total of 66000 patients, directly solving the pain points of pharmaceutical companies in patient recruitment and patient management, Helping patients connect with the latest treatment solutions, helping research centers conduct clinical research more effectively, improving the efficiency of new drug research and development, accelerating the launch of new drugs, connecting patients with hope, and benefiting patients worldwide.
He said, "We uphold the vision of bringing hope to patients and fulfill the mission of connecting patients and hope. We hope to work with experts, scholars, and medical institutions to help more new drugs and enterprises go public. We look forward to all parties exploring new cooperation in the innovative medical highland of Boao Lecheng Pilot Zone, bringing hope to more patients
Chen Pingyan, a professor at the Department of Biostatistics at Southern Medical University and Executive Dean of Hainan Zhenyan Institute, shared the relevant guidelines system for real world research in China, how real world evidence supports clinical research and development of new drugs, and the scope of application of real world evidence under the theme of "Real World Research Assists Clinical Research and Development of New Drugs".
Experts and scholars gather to discuss the innovative development of clinical research
New Target Therapy Sub Forum for Lung Cancer
Under the leadership of Professor Wang Yongsheng from the Respiratory and Critical Care Medicine Department of Nanjing Gulou Hospital, Professor Shen Zhixiang from the Hematology Department of Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine and Professor Han Yuchen from the Pathology Department of Shanghai Chest Hospital respectively presented theme reports on "Experience Sharing of Drug Clinical Trial Data Monitoring Committee in Solid Tumor Research" and "Detection and Progress of Rare Driver Genes for Lung Cancer".
Professor Han Yuchen, Department of Pathology, Shanghai Chest Hospital
At the round table forum on the theme of "Collaborative Innovation, Assisting Cancer Patients to Connect with Clinical New Drug Precision Treatment Research", Professor Lv Dongqing from the Respiratory Department of Taizhou Hospital in Zhejiang shared his experience in recruiting lung cancer projects. Professor Cheng Peng, Department of Oncology, Affiliated Hospital of Nanyang Medical College, Professor Guo Jindong, Department of Radiotherapy, Shanghai Chest Hospital, Professor Huang Zhiyong, thoracic surgery, Nanfang Hospital of Southern Medical University, Professor Liu Qun, Department of Respiratory Medicine, the First Affiliated Hospital of Xiamen University, Professor Luo Suxia, Department of Oncology, Henan Cancer Hospital, and Professor Li Yan, Lung Cancer Center, West China Hospital, Sichuan University conducted in-depth discussions on the above issues, sharing cutting-edge insights and forward-looking ideas.
Alzheimer's disease (AD) new drug treatment sub forum
Under the leadership of Kang Wenyan, Chief Physician of the Department of Neurology at Ruijin Hospital Affiliated to Shanghai Jiao Tong University Medical College and Director of Medical Operations at Hainan Hospital of Ruijin Hospital, the Alzheimer's Disease (AD) New Drug Treatment Sub Forum opened a brilliant academic feast. Dr. Wang Yaning, CEO of Langlai Technology, interprets the approval of aducanumab and the global progress of AD drug research and development from the perspective of FDA. Professor Zhou Aihong from the Department of Neurology at Beijing Xuanwu Hospital wrote a book titled "A β Overview of Clinical Research on Monoclonal Antibiotics in China ".
Kang Wenyan
Dr. Wang Yaning, CEO of Langlai Technology
Professor Zhou Aihong from the Department of Neurology at Beijing Xuanwu Hospital
The roundtable forum on the theme of "Assisting Patients in Integrating New Drugs or Clinical Practice of New Drugs" is hosted by Professor Yang Yu from the Department of Neurology at the First Hospital of Jilin University. Kang Wenyan, Deputy Chief Physician of the Department of Neurology at Ruijin Hospital Affiliated to Shanghai Jiao Tong University Medical College, and Director of Medical Operations at Ruijin Hospital Hainan Hospital, shared the construction of the Brain Disease Center at Ruijin Hainan Hospital. Professor Guo Aihua, Department of Neurology at Guangzhou First People's Hospital, shared his experience in recruiting AD patients. Professor Ma Chi from the Department of Neurology of the Fourth Affiliated Hospital of Harbin Medical University, Professor Wang Hongxin from the Department of Neurology of Jinan Central Hospital, Xiao Tingting, attending physician from the Department of Neurology of the People's Hospital of Wuhan University, and Professor Yang Shaoqing from the Department of Neurology of the Second Affiliated Hospital of Guangzhou Medical University had a heated discussion about this.
New Drug Sub Forum on Inflammatory Bowel Disease (IBD) in the Digestive Field
The new drug sub forum for inflammatory bowel disease (IBD) in the field of digestion is chaired by Professor Sun Jing from the Department of Gastroenterology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University Medical College. Professor Cao Qian from the Department of Gastroenterology at Run Run Run Shaw Hospital and Professor Chen Baili from the Department of Gastroenterology at the First Affiliated Hospital of Sun Yat sen University respectively gave themed reports on "New Advances in Global IBD Drug Research and Development" and "Overview of Clinical Research on New Drugs under Development in China", sharing the progress of new drug research and development for inflammatory bowel disease (IBD) in the digestive field both domestically and internationally.
Ding Ni, the nurse in charge of the Department of Gastroenterology of the Sixth Affiliated Hospital of Sun Yat sen University, Xu Jiaqin, the attending physician of the Department of Gastroenterology of Anhui Provincial Hospital, shared the experience of recruiting IBD patients, Professor Chao Kang, the Department of Gastroenterology of the Sixth Affiliated Hospital of Sun Yat sen University, Professor Guo Hong, the Department of Gastroenterology of Chongqing People's Hospital, and Professor Liu Fei, the Department of Gastroenterology of Dongfang Hospital of Tongji University Professor Shi Huaxiu from the Department of Gastroenterology at Zhongshan Hospital Affiliated to Xiamen University expressed his own opinions and shared professional insights on the topic of "IBD patient management and patient recruitment practice".
The gathering of elites to seek development plans provides a rare opportunity for clinical doctors, researchers, scholars, and others to exchange ideas. It establishes a more effective communication platform between clinical frontline and pharmaceutical research and development, which will help promote the development and implementation of new drugs in China.
This summit forum is guided by the Management Bureau of Hainan Boao Lecheng International Medical Tourism Pilot Zone, and hosted by Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Hainan Hospital (Hainan Boao Research Hospital), Hainan Zhenyan Institute, and Jiexin Pharmaceutical/Xinhua Pharmaceutical.